A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

* Patients must have histologically or cytologically confirmed malignant solid tumor. * Patients who are amenable to standard combination chemotherapy of carboplatin and paclitaxel. * Patients should have received less than or equal to 1 prior chemotherapy regimens for advanced stage disease. * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2. * Patients must have normal organ and marrow function

* Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or the adverse events due to agents administered more than 3 weeks earlier have not recovered to less than grade 2. * Known history of allergic reactions to carboplatin or cremophor-paclitaxel. * Patients who have previously received a poly(ADP-ribose) polymerase (PARP) inhibitor. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active systemic infection requiring treatment, symptomatic congestive heart failure, angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * History of seizure disorder. * Hepatitis B surface antigen (HBsAg) positive, Hepatitis C virus (HCV) antibody positive or Human immunodeficiency virus (HIV)-positive patients.